venetoclax + atezolizumab

**Venetoclax + atezolizumab is an experimental anticancer combination therapy under clinical development, most frequently studied with obinutuzumab as a triplet regimen.** - Venetoclax is a small molecule inhibitor of B-cell lymphoma 2 (BCL-2), promoting apoptosis in cancer cells. - Atezolizumab is a humanized monoclonal antibody targeting programmed death-ligand 1 (PD-L1), thus preventing immune escape by tumor cells. - The combination aims to simultaneously induce cancer cell death (via BCL-2 inhibition) and reactivate immune anti-tumor activity (via PD-L1 blockade). - Preclinical and early clinical studies indicate clinical activity in diseases such as chronic lymphocytic leukemia (CLL), Richter transformation (diffuse large B-cell lymphoma variant), and small lymphocytic lymphoma, especially in regimens alongside obinutuzumab[1][2][3][4]. - Main adverse events include neutropenia, immune-mediated side effects (e.g., colitis, pneumonitis), and a risk of severe infections[2][3][4].